Latest Oncology News

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

June 27th 2022

Kristi Rosa

The FDA has placed a partial clinical hold on the phase 1/2 NUV-422-02 trial evaluating the selective small molecule CDK2/4/6 inhibitor NUV-422 in patients with solid tumors such as high-grade glioma, hormone receptor–positive advanced breast cancer, and metastatic castration-resistant prostate cancer.

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

June 27th 2022

Caroline Seymour

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk, early breast cancer who have received neoadjuvant or adjuvant chemotherapy.

Leukemia Pioneers Chronicle Career Experiences and Milestones

June 27th 2022

OncLive Staff

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

June 27th 2022

Jason Harris

The combination of anlotinib and sintilimab was found to provide a long-term survival benefit to patients with previously treated advanced cervical cancer.

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

June 27th 2022

Chris Ryan

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of trastuzumab deruxtecan monotherapy for patients with metastatic HER2-positive breast cancer who have received at least 1 prior anti–HER2-based regimen.

Latest Oncology Videos

Overview of SCLC and Importance of Early Diagnosis

Use of the TNM Staging System in SCLC

Dr. Ghosh on the Safety Data Seen With Liso-cel in LBCL

Mechanism of Action of Ruxolitinib

Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

HER2 Dual Blockade in Early Stage HER2+ Breast Cancer

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

Frontline Treatment Strategies for HR+/HER2- Breast Cancer

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

NSCLC: Immunotherapy in Patients With Concomitant KRAS/TP53 Mutations

I/O Therapy in KRAS-Mutant NSCLC With Concomitant STK11 or KEAP1 Mutations

Dr. Lunning on the FDA Approval of Liso-cel in LBCL

Epcoritamab + Gemcitabine + Oxaliplatin in R/R DLBCL Transplant Ineligible Patients Induces High Response Rate Even in Pts Failing CAR T Therapy

Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast Cancer

Dr. Nakayama on the Current Treatment Landscape of Ovarian Cancer

Dr. Khorana on Rates of Young-Onset Pancreatobiliary Adenocarcinoma

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

Dr. Kamath on the Inclusion of Underrepresented Groups in Clinical Trials

Dr. Tawbi on the Safety of Relatlimab Plus Nivolumab in Melanoma

Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer

MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Unmet Needs and Future Perspectives in AML

Targeted Therapy in Patients with AML and IDH1/IDH2 Mutations

All Oncology News

Dr. Wenham on the Role of ADCs in Ovarian Cancer

June 20th 2022

Robert M. Wenham, MD

Robert Wenham, MD, MS, FACOG, FACS, discusses the role of antibody-drug conjugates in ovarian cancer.

Dr. Matulonis on the Current Treatment Landscape of Recurrent Ovarian Cancers

June 20th 2022

Ursula A. Matulonis, MD

Ursula A. Matulonis, MD, discusses the current treatment landscape of recurrent ovarian cancer.

Nemtabrutinib Generates Responses, Displays Manageable Safety in CLL/SLL

June 20th 2022

Chris Ryan

Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Cilta-Cel Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

June 20th 2022

Chris Ryan

A single infusion of the CAR T-cell therapy ciltacabtagene autoleucel produced deep and durable responses in patients with relapsed/refractory multiple myeloma with a manageable toxicity profile, according to long-term follow-up data of the phase 1b/2 CARTITUDE-1 trial.

Trastuzumab Deruxtecan Elicits Statistically Significant PFS in HR-Positive/HER2-Low Breast Cancer

June 20th 2022

Ryan Scott

Fam-trastuzumab deruxtecan-nxki demonstrated a statistically significant benefit in progression-free survival in patients with HER2-low metastatic breast cancer, meeting the primary end point of the phase 3 DESTINY-Breast04 trial and changing the standard of care for this patient population.

Yale Research Reveals “Biologically Older” Tissue in Patients with Breast Cancer

June 20th 2022

Yale Cancer Center

An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors.

European Medicines Agency Validates Type II Variation Application for Liso-cel in Second-line LBCL

June 20th 2022

Caroline Seymour

The European Medicines Agency has verified its type II variation application to extend the indication for lisocabtagene maraleucel to include the treatment of adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma, who are refractory or have relapsed within 12 months of initial therapy and are candidates for hematopoietic stem cell transplant.

A Molecular Revolution Is Underway in Thoracic Oncology

June 20th 2022

Brittany Lovely

Targetable alterations including BRAF V600E, EGFR exon 20 insertions, KRAS G12C mutations, MET exon 14 alterations, NTRK and RET rearrangements have taken up recent focus for investigators as data are pushing novel agents through the regulatory processes.

Is There a Role for PD-L1 Inhibitors in EGFR-Mutant or ALK-Rearranged NSCLC?

June 20th 2022

John Heymach, MD, PhD

John Heymach, MD, PhD, discusses the poor outcomes that have been observed with immunotherapy in patients with NSCLC and EGFR mutations or ALK rearrangements.

T-VEC Plus Pembrolizumab Generates Promising Responses, Safety in PD-1–Refractory Advanced Melanoma

June 20th 2022

Caroline Seymour

Adding talimogene laherparepvec to pembrolizumab led to encouraging responses with a manageable safety profile in patients with advanced melanoma who progressed on prior anti–PD-1 therapy, most notably in the adjuvant setting, according to findings from the phase 2 MASTERKEY-115 trial.

Overcoming Barriers to Molecular Profiling in NSCLC Management

June 20th 2022

John Heymach, MD, PhD

Expert perspectives on the prevalence of molecular profiling in NSCLC, and the unmet needs and barriers preventing the uptake of routine molecular testing.

Dr. Gupta on the Design of the PARADIGM Study in Urothelial Cancer

June 19th 2022

Shilpa Gupta, MD, Cleveland Clinic

Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Botta on the Rationale of Investigating CT041 in Gastric and Pancreatic Cancers

June 19th 2022

Gregory P. Botta, MD, PhD

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. George on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 19th 2022

Mridula George, MD

Mridula George, MD, discusses the clinical implications of the phase 3 DESTINY-Breast04 trial in breast cancer.

Dr. Khan on the Rationale of Examining Disparate Outcomes in GI Tract Cancer Surgery

June 19th 2022

Sajid A Khan MD, FACS, FSSO

Sajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.

See All News